Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001802768-24-000045
Filing Date
2024-08-08
Accepted
2024-08-08 09:02:22
Documents
70
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rprx-20240630.htm   iXBRL 10-Q 2247844
2 EX-31.1 rprx-20240630ex311.htm EX-31.1 9255
3 EX-31.2 rprx-20240630ex312.htm EX-31.2 9291
4 EX-32 rprx-20240630ex32.htm EX-32 5011
  Complete submission text file 0001802768-24-000045.txt   9999660

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rprx-20240630.xsd EX-101.SCH 68872
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rprx-20240630_cal.xml EX-101.CAL 87565
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rprx-20240630_def.xml EX-101.DEF 367701
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rprx-20240630_lab.xml EX-101.LAB 731326
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rprx-20240630_pre.xml EX-101.PRE 511953
72 EXTRACTED XBRL INSTANCE DOCUMENT rprx-20240630_htm.xml XML 1664336
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39329 | Film No.: 241186293
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)